Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: Findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry

Internal Medicine Journal

Volumn 46, Issue 1, 2016, Pages 71-79

  Blombery, P ^a,b   Kivivali, L ^b   Pepperell, D ^b,c   Mcquilten, Z ^b   Engelbrecht, S ^b,d   Polizzotto, M N ^b,e,f   Phillips, L E ^b   Wood, E ^b,g   Cohney, S ^b,h,i  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c FIONA STANLEY HOSPITAL   (Australia)

^d GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g MONASH MEDICAL CENTRE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ Western and Royal Melbourne Hospitals   (Australia)

Author keywords

ADAMTS13; Registry; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLERGIC REACTION; ARTICLE; AUSTRALIA; AUSTRALIAN; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PATIENT INFORMATION; PLASMA TRANSFUSION; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; DISEASE MANAGEMENT; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTER; THROMBOSIS; TIME FACTOR; TRENDS;

ADULT; AUSTRALIA; DISEASE MANAGEMENT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; THROMBOSIS; TIME FACTORS;

EID: 84969389725     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12935     Document Type: Article

References (35)

1. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
2. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
3. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
4. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-35.
5. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3: 1432-6.
6. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008; 142: 819-26.
7. Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 1995; 70: 319-23.
8. George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology/The Education Program of the American Society of Hematology American Society of Hematology Education Program 2012; 2012: 604-9.
9. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 1201-8.
10. Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, Szczepiorkowski ZM et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014; 29: 148-67.
11. Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014; 124: 211-9.
12. Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9: 283-301.
13. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
14. Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990; 34: 169-74.
15. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 2001; 16: 134-8.
16. McCarthy LJ, Dlott JS, Orazi A, Waxman D, Miraglia CC, Danielson CF. Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Japanese Society Dialysis Therapy 2004; 8: 80-6.
17. Scully M, Longair I, Flynn M, Berryman J, Machin SJ. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007; 93: 154-8.
18. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004; 14: 39-44.
19. Ozier Y, Muller JY, Mertes PM, Renaudier P, Aguilon P, Canivet N et al.. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion 2011; 51: 2102-10.
20. Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 2010; 89: 591-6.
21. Moake JL, Rudy CK, Troll JH, Schafer AI, Weinstein MJ, Colannino NM et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985; 20: 73-9.
22. Ahmad HN, Thomas-Dewing RR, Hunt BJ. Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura. Eur J Haematol 2007; 78: 449-52.
23. Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pene F et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 2012; 52: 2436-44.
24. Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion 2005; 45: 41-9.
25. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-53.
26. Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40: 104-11.
27. Rinott N, Mashiach T, Horowitz NA, Schliamser L, Sarig G, Keren-Politansky A et al. A 14-year experience in the management of patients with acquired immune thrombotic thrombocytopenic purpura in Northern Israel. Rituximab adjuvant therapy in patients with refractory and relapsed disease is both effective and cost beneficial. Acta Haematol 2015; 134: 170-76.
28. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013; 11: 481-90.
29. Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 2014; 124: 204-10.
30. Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981; 246: 1931-3.
31. Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987; 24: 194-201.
32. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lammle B, George JN. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 873-87.
33. Zhou A, Mehta RS, Smith RE. Outcomes of platelet transfusion in patients with thrombotic thrombocytopenic purpura: a retrospective case series study. Ann Hematol 2015; 94: 467-72.
34. Ong M, Veillon D, Cotelingam J. Is platelet transfusion necessary prior to a central venous catheter placement in thrombotic thrombocytopenic purpura patients? J La State Med Soc 2012; 164: 283-4.
35. Duffy SM, Coyle TE. Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura. J Clin Apher 2013; 28: 356-8.